Dr. Julie Goodman, an epidemiologist and a Diplomate of the American Board of Toxicology, is a principal at Gradient, an environmental consulting firm. She is also on the adjunct faculty in the department of epidemiology at the Harvard School of Public Health. Her primary responsibilities at Gradient include the design, oversight, analysis, and interpretation of epidemiology studies as well as the evaluation of chemical toxicology data, apparent disease clusters, and chemical exposures.
Much of Dr. Goodman’s work focuses on assessing the weight of evidence regarding chemical exposures and potential health risks. She also has done considerable work evaluating the shape of dose-response curves at low doses, the toxicological significance of functional changes, and the use of epidemiology and toxicology data to address questions regarding appropriate dose-response models and the identification of responses at ambient exposures.
Dr. Goodman has authored and co-authored over 50 original research articles, review articles, and book chapters on a wide variety of topics related to epidemiology, toxicology, and risk assessment. She also has presented scientific findings and analyses to community groups and regulatory and legislative bodies, including the US Congress.
Topics on which she has published and presented include an evaluation of health risks from low doses of bisphenol A, commentary on the proposal for linear low-dose extrapolation for non-cancer health effects, and assessments of health risks (and differentiating adverse vs. non-adverse effects) from the criteria pollutants (NO2, O3, PM, and SO2) at low exposure levels.
Before joining Gradient, Dr. Goodman was a Cancer Prevention Fellow at the National Cancer Institute. She received an SB degree in Environmental Engineering from the Massachusetts Institute of Technology in 1996, and an Sc.M. in Epidemiology in 2000 and a Ph.D. in Environmental Health Sciences/Toxicology in 2002 from the Johns Hopkins Bloomberg School of Public Health.